title: Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas.
abstract: OBJECTIVE
  To determine the clinical efficacy and safety of a cremophor-free formulation of paclitaxel (Paccal Vet, Oasmia Pharmaceuticals) in dogs with mast cell tumours.
  
  
  METHODS
  Paccal Vet was administered at a median dose of 145 (range, 135 to 150) mg/m(2) intravenously once every 21 days for three cycles to 29 dogs with macroscopic grade 2 or 3 mast cell tumour. Efficacy was assessed by tumour response (Response Evaluation Criteria in Solid Tumours version 1.0) and performance status score. Progression-free survival, quality of life and safety/adverse events were also evaluated. Clinical safety was assessed by clinicopathological analyses and recording of adverse events.
  
  
  RESULTS
  Complete or partial response was observed in 59% of dogs. Performance status score remained constant or improved for 20 dogs and decreased by one grade for 9 dogs. Median time to progression was 247 (range, 42 to 268) days. Expected, transient frequently subclinical adverse events (primarily grade 3/4 neutropenia and grade 1/2 leukopenia) were observed in the majority of dogs. Nine dogs were euthanased and one dog died due to disease progression.
  
  
  CONCLUSIONS
  Paccal Vet appears to be a clinically safe and effective treatment for canine mast cell tumours. Further controlled confirmatory investigation is warranted.
authors.affiliation: Department of Clinical Sciences, Center of Clinical Comparative Oncology (C3O), Swedish University of Agricultural Sciences (SLU), SE-750 07, Uppsala, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Rivera
authors.forename: N
authors.initials: N
authors.lastname: Akerlund-Denneberg
authors.forename: K
authors.initials: K
authors.lastname: Bergvall
authors.forename: M
authors.initials: M
authors.lastname: Kessler
authors.forename: A
authors.initials: A
authors.lastname: Rowe
authors.forename: M
authors.initials: M
authors.lastname: Willmann
authors.forename: G
authors.initials: G
authors.lastname: Persson
authors.forename: G
authors.initials: G
authors.lastname: Kastengren Fröberg
authors.forename: S
authors.initials: S
authors.lastname: Westberg
authors.forename: H
authors.initials: H
authors.lastname: von Euler
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000188:drug therapy* / Q000523:psychology; D004285:Dogs; D005260:Female; D007262:Infusions, Intravenous / Q000662:veterinary; D008297:Male; D034801:Mastocytoma / Q000188:drug therapy / Q000523:psychology / Q000662:veterinary*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life; D013548:Sweden; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel